Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-09-25
2007-09-25
Chan, Christina (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388250, C530S389300, C530S866000, C435S325000, C435S328000, C435S337000, C435S346000, C424S133100, C424S145100, C424S809000
Reexamination Certificate
active
09464303
ABSTRACT:
The invention relates to methods and products for regulating lectin complement pathway associated complement activation. The methods include both in vitro and in vivo methods for inhibiting lectin complement pathway associated complement activation. The methods are accomplished by contacting a mammalian cell having surface exposed MBL ligand with an effective amount of a mannan binding lectin inhibitor to inhibit lectin complement pathway associated complement activation. The mannan binding lectin inhibitor may be administered to a subject to prevent cellular injury mediated by lectin complement pathway associated complement activation. The products of the invention include compositions of a mannan binding lectin inhibitor. The mannan binding lectin inhibitor is an isolated mannan binding lectin binding peptide that selectively binds to a human mannan binding lectin epitope and that inhibits lectin complement pathway associated complement activation. The products also include hybridoma cell lines and pharmaceutical compositions.
REFERENCES:
patent: 5270199 (1993-12-01), Ezekowitz
patent: 5616311 (1997-04-01), Yen
patent: 06121695 (1994-05-01), None
patent: 07238100 (1995-09-01), None
patent: WO89/01519 (1989-02-01), None
patent: WO90/08549 (1990-08-01), None
patent: WO91/06010 (1991-05-01), None
patent: WO93/18775 (1993-09-01), None
patent: WO97/31121 (1997-08-01), None
patent: WO99/39209 (1999-08-01), None
patent: WO 00/35483 (2000-06-01), None
patent: WO 01/12212 (2001-02-01), None
Janeway et al. Immunobiology, 3rd Edition, Garland Press, 1997, p. 13.8.
Pierce Catalog (1995) p. T-19 and T-20 Pierce Corp.
Janeway et al Immunobiology (1999) Fourth Edition Garland Press, p. 87.
Abaza et a;. J. of Protein Chemistry, 11(5):433-444, (1992).
Sato et al., Molecular characterization of a novel serine protease involved in activation of the complement system by mannose-binding protein. International Immunology. Apr. 1994, vol. 6, No. 4, pp. 665-669.
Endo et al., Exon structure of the gene encoding the hamanmannose-binding protein-associated serine protease light chain: comparison with complement C1r and C1s genes. International Immunology. Sep. 1996, vol. 8, No. 9, pp. 1355-1358.
Thiel, et al., A second serine protease associated with mannan-binding lectin that activates complement. Nature. Apr. 1997, vol. 386, pp. 506-510.
Endo et al., Two lineages of mannose-binding lectin-associated serine protease (MASP) in vertebrates, J. Immunology. Nov. 1998, vol. 161, pp. 4924-4930.
International Search Report—Intl. Appl. No., PCT/US99/29919—Dec. 15, 1999.
Amsterdam. E.A. et al., “Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs”,Am J Physiol Heart Circ Physiol, 1995, 268:H448-H457.
Endo, Y. et al., “Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy,”Nephrol Dial Transplant, Aug. 1998, 13(8):1984-1990.
Jack, D.L. et al., Activation of complement by mannose-binding lectin on isogenic mutants ofNeisseria meningitidisserogroup B,J. Immunol, Feb. 1998, 160(3):1346-53 Abstract Only.
Vorup-Jensen, T. et al., “MASP-2, the C3 Convertase Generating Protease of the MBLectin Complement Activating Pathway”,Immunobiol., vol. 199, 1998, pp. 348-357.
Konami, Y. et al., “Correlation between carbohydrate-binding specificity and amino acid sequence of carbohydrate-binding regions ofCytisus-type anti-H(O) lectins”,FEBS Letters, vol. 304, No. 2.3, pp. 129-135, Jun. 1992.
Lennon, P.F. et al., “Complement-induced endothelial dysfunction in rabbits: mechanisms, recovery, and gender differences”,Am J Physiol Heart Circ Physiol, 1996, 270:H1924-H1932.
Linder, E. et al., “Activation of complement by cytoskeletal intermediate filaments”,Nature, vol. 278, Mar. 8, 1979, pp. 176-178.
Linder, E., “Antibody-independent Binding of C1q and Activation of Serium Complement by Human Skin in Vitro”< The Journal of Investigative Dermatology, vol. 78, No. 2, 1982, pp. 116-150.
Linder, E. et al., “Activation of Complement by Intermediate Filaments of Glomerular Epithelial Cells”,Clinical Immunology and Immunopathology, vol. 40, 1986, pp. 265-275.
Shikhman, A.R. et al., “Cytokeratin Peptide SFGSGFGGGY Mimics N-Acetyl-β-D-Glucosamine in Reaction with Antibodies and Lectins, and Induces In Vivo and Anti-Carbonhydrate Antibody Response” ,The Journal of Immunology, 1994, pp. 5593-5606.
Super, M. et al., “The level of mannan-binding protein regulates the binding of complement-derived opsonins to mannan and zymosan at low serum concentrations,”Clin Exp Immunol., 1990, vol. 79, pp. 144-150.
Terai, I. et al., “Human serum mannose-binding lectin (MBL)-associated serine protease-1 (MASP-1): determination of levels in body fluids and identification of two forms in serum”,Clin Exp Immunol, 1997, vol. 110, pp. 317-323.
Turner, M.W., “The lectin pathway of complement activation”, ResImmunol, Feb. 1996, 147(2):110-5.
Vakeva, A.P. et al., “Myocardial Infarction and Apoptosis After Myocardial Ischemia and Reperfusion. Role of the Terminal Complement Components and Inhibition by Anti-C5 Therapy”,Circulation, vol. 97, Jun. 9, 1998, pp. 2259-2267.
Agah, A. et al., “Isolation, Characterization, and Cloning of Porcine Complement Component C7”, The Journal of Immunology, 2000, pp. 1059-1065, The American Association of Immunologists.
Collard, C.D. et al., “Reoxygenation of hypoxic human umbillical vein endothelial cells (HUVECs) activates the lectin complement pathway (LCP)”,FASEB Journal, Mar. 17, 1998, p. 29A Abstract, vol. 12, No. 4, Meeting Info: Annual Meeting of Professional Research Scientists on Experimental Biology 98, Part 1, San Francisco, CA, USA, Apr. 18-22, 1998, Federation of American Societies of EX.
Collard, C.D. et al., “Hypoxia-induced expression of complement receptor type 1 (CR1, CD35) in human vascular endothelial cells”,AJP-Cell Physiology, Feb. 1999, pp. C450-C458, vol. Issue 2.
Collard, C.D. et al., “Endothelial reoxygenation activates the lectin complement pathway: Inhibition with anti-human mannose binding lectin (MBL) therapy”,Molecular Immunology, Mar.-Apr. 1999, p. 278 Abstract, vol. 36, No. 4-5, Meeting Info: 7thEuropean Meeting on Complement in Human Disease, Helsinki, Finland, Jun. 17-20, 1999.
Collard, C.D. et al., “Complement activation following oxidative stress”,Molecular Immunology, 1999, pp. 941-948, vol. 36, Elsevier Science Ltd.
Collard, C.D. et al., “Complement Activation after Oxydative Stress, Role of the Lectin Complement Pathway”,American Journal of Pathology, May 2000, pp. 1549-1556, vol. 156, No. 5, American Society of Investigative Pathology.
Collard, C.D. et al., “Endothelial oxidative stress increases cytokeratin 1 (K1) expression and human mannose-binding (MBL) deposition”,Immunopharmacology, Aug. 2000, p. 85, Abstract, vol. 49, No. 1-2, Print Meeting Info: XVIIITH International Complement Workshop, Salt Lake City, Utah, USA, Jul. 23-27, 2000.
Fitch, J.C.K. et al., “Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery with Cardiopulmonary Bypass”,Circulation, Dec. 21/28, 1999, pp. 2499-2506, American Hearth Association.
Lhotta, K. et al., “Glomerular deposition of mannose-binding lectin in human glomerulonephritis”,Nephrology Dialysis Transplantation, 1999, pp. 881-886, vol. 14, European Renal Association, European Dialysis and Transplant Association.
Linder, E., “Binding of C1q and Complement Activation by Vascular Endothelium”,The Journal of Immunology, Feb. 1981, pp. 648-658, vol. 126 , No. 2.
Turner, M.W., “Mannose-binding lectin: the pluripotent molecular of the innate immune system”,Review Immunology To
Collard Charles D.
Stahl Gregory L.
Brigham and Women's Hospital, Inc.
Chan Christina
VanderVegt F. Pierre
Wolf Greenfield & Sacks P.C.
LandOfFree
Methods and products for regulating lectin complement... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and products for regulating lectin complement..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and products for regulating lectin complement... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3769297